|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||130.02 - 132.08|
|52-week range||120.90 - 148.32|
|PE ratio (TTM)||280.89|
|Earnings date||17 Apr 2018|
|Forward dividend & yield||3.36 (2.59%)|
|1y target est||150.86|
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Johnson & Johnson securities between February 22, 2013 and February 7, 2018.
Achillion Pharmaceuticals' (ACHN) fourth-quarter loss wider than estimates. The company is focusing on operational restructuring to save costs.
Looking for the highest-yielding dividend stocks can cause you to miss some of the best investments. Here are three with yields around 2%, but they could outperform many stocks with much higher yields.
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Johnson & Johnson securities during the period between February 22, 2013 and February 7, 2018, inclusive .
ohnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The following statement is being issued by Levi & Korsinsky, LLP:
Novartis: What Are the Major Growth Drivers for 2018? Aimovig, which is Novartis’s (NVS) investigational migraine prophylaxis therapy, is currently under review by the FDA and the European Medicines Agency (or EMA). More than 10.0% of the adults in the world suffer from migraine.
Law Offices of Howard G. Smith continues its investigation on behalf of Johnson & Johnson Investors investors concerning the Company and its officers’ possible violations of federal securities laws.
BSX Stock Recovers after a Robust 4Q17: What's to Come? In December 2017, the Tax Cuts and Jobs Act was passed in the US Senate. The healthcare industry has seen the impact of the tax reform, with most US healthcare companies reporting one-time financial effects on their balance sheets.
With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q4 release.
Johnson & Johnson is seeking buyers for its sterilization products division, people familiar with the matter said, as the health-care conglomerate continues to sell off non-core assets.